Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;26(7):847-58.
doi: 10.1007/s00384-011-1176-x. Epub 2011 Apr 5.

Molecular profiles and clinical outcome of stage UICC II colon cancer patients

Jörn Gröne  1 , Dido Lenze, Vindi Jurinovic, Manuela Hummel, Henrik Seidel, Gabriele Leder, Georg Beckmann, Anette Sommer, Robert Grützmann, Christian Pilarsky, Ulrich Mansmann, Heinz-Johannes Buhr, Harald Stein, Michael Hummel
Affiliations

Molecular profiles and clinical outcome of stage UICC II colon cancer patients

Jörn Gröne et al. Int J Colorectal Dis. 2011 Jul.

Abstract

Purpose: Published multigene classifiers suggesting outcome prediction for patients with stage UICC II colon cancer have not been translated into a clinical application so far. Therefore, we aimed at validating own and published gene expression signatures employing methods which enable their reconstruction in routine diagnostic specimens.

Methods: Immunohistochemistry was applied to 68 stage UICC II colon cancers to determine the protein expression of previously published prognostic classifier genes (CDH17, LAT, CA2, EMR3, and TNFRSF11A). RNA from macrodissected tumor samples from 53 of these 68 patients was profiled on Affymetrix GeneChips (HG-U133 Plus 2.0). Prognostic signatures were generated by "nearest shrunken centroids" with cross-validation. Previously published gene signatures were applied to our data set using "global tests" and leave-one-out cross-validation

Results: Correlation of protein expression with clinical outcome failed to separate patients with disease-free follow-up (group DF) and relapse (group R). Although gene expression profiling allowed the identification of differentially expressed genes ("DF" vs. "R"), a stable classification/prognosis signature was not discernable. Furthermore, the application of previously published gene signatures to our data was unable to predict clinical outcome (prediction rate 75.5% and 64.2%; n.s.). T-stage was the only independent prognostic factor for relapse with established clinical and pathological parameters including microsatellite status (multivariate analysis).

Conclusions: Our protein and gene expression analyses do not support application of molecular classifiers for prediction of clinical outcome in current routine diagnostic as a basis for patient-orientated therapy in stage UICC II colon cancer. Further studies are needed to develop prognosis signatures applicable in patient care.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 - PubMed
    1. Blood. 2008 Oct 15;112(8):3425-33 - PubMed
    1. Clin Cancer Res. 2007 May 15;13(10):2946-54 - PubMed
    1. J Biol Chem. 2001 Jun 1;276(22):18863-70 - PubMed
    1. J Biol Chem. 2000 Jul 14;275(28):21525-31 - PubMed

Substances